These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22396745)

  • 41. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.
    Jaeckle M; Khaykin P; Haberl A; De Leuw P; Schüttfort G; Stephan C; Wolf T
    Int J STD AIDS; 2016 Nov; 27(13):1170-1179. PubMed ID: 26429890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.
    Rozera G; Fabbri G; Lorenzini P; Mastrorosa I; Timelli L; Zaccarelli M; Amendola A; Vergori A; Plazzi MM; Cicalini S; Antinori A; Capobianchi MR; Abbate I; Ammassari A
    PLoS One; 2017; 12(10):e0187095. PubMed ID: 29077766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
    Buzón MJ; Codoñer FM; Frost SD; Pou C; Puertas MC; Massanella M; Dalmau J; Llibre JM; Stevenson M; Blanco J; Clotet B; Paredes R; Martinez-Picado J
    PLoS Pathog; 2011 Oct; 7(10):e1002314. PubMed ID: 22046128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
    Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
    AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
    Puertas MC; Gómez-Mora E; Santos JR; Moltó J; Urrea V; Morón-López S; Hernández-Rodríguez A; Marfil S; Martínez-Bonet M; Matas L; Muñoz-Fernández MA; Clotet B; Blanco J; Martinez-Picado J
    J Antimicrob Chemother; 2018 Jul; 73(7):1940-1948. PubMed ID: 29635527
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
    Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):125-33. PubMed ID: 17721395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
    Skiest DJ; Cohen C; Mounzer K; Haigney Z; Barker D; Gottlieb M; Bellman PC; Dejesus E; Khanlou H; Ruane PJ; Hsiao CB; Abriola K; Rashbaum B; Bellos N; Ward D; Colson A; Santiago F; Habel A; Garb J
    HIV Clin Trials; 2011; 12(3):131-40. PubMed ID: 21684853
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dynamics of Simian Immunodeficiency Virus Two-Long-Terminal-Repeat Circles in the Presence and Absence of CD8
    Policicchio BB; Cardozo EF; Sette P; Xu C; Haret-Richter G; Dunsmore T; Apetrei C; Pandrea I; Ribeiro RM
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29643246
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistent high levels of immune activation and their correlation with the HIV-1 proviral DNA and 2-LTR circles loads, in a cohort of Mexican individuals following long-term and fully suppressive treatment.
    Orta-Resendiz A; Viveros-Rogel M; Fuentes-Romero LL; Vergara-Mendoza M; Romero-Rodriguez DP; Muñoz-Lopez M; Zancatl-Diaz ML; Vidal-Laurencio EY; Rodriguez-Diaz RA; Soto-Ramirez LE
    Int J Infect Dis; 2020 Nov; 100():184-192. PubMed ID: 32829045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
    Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
    AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.
    Eron JJ; Clotet B; Durant J; Katlama C; Kumar P; Lazzarin A; Poizot-Martin I; Richmond G; Soriano V; Ait-Khaled M; Fujiwara T; Huang J; Min S; Vavro C; Yeo J;
    J Infect Dis; 2013 Mar; 207(5):740-8. PubMed ID: 23225901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
    Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
    Amendola A; Sberna G; Forbici F; Abbate I; Lorenzini P; Pinnetti C; Antinori A; Capobianchi MR
    PLoS One; 2020; 15(2):e0228192. PubMed ID: 32023284
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy.
    Noguera-Julian M; Casadellà M; Pou C; Rodríguez C; Pérez-Álvarez S; Puig J; Clotet B; Paredes R
    Virol J; 2013 Dec; 10():350. PubMed ID: 24304606
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
    Matheron S; Descamps D; Gallien S; Besseghir A; Sellier P; Blum L; Mortier E; Charpentier C; Tubiana R; Damond F; Peytavin G; Ponscarme D; Collin F; Brun-Vezinet F; Chene G;
    Clin Infect Dis; 2018 Sep; 67(8):1161-1167. PubMed ID: 29590335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study.
    Luo L; Wang N; Yue Y; Han Y; Lv W; Liu Z; Qiu Z; Lu H; Tang X; Zhang T; Zhao M; He Y; Shenghua H; Wang M; Li Y; Huang S; Li Y; Liu J; Tuofu Z; Routy JP; Li T
    BMC Infect Dis; 2019 Mar; 19(1):257. PubMed ID: 30871484
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
    Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Gatell JM; Kumar PN; Rockstroh JK; Schechter M; Markowitz M; Yeni P; Loutfy MR; Lazzarin A; Lennox JL; Strohmaier KM; Wan H; Barnard RJ; Nguyen BY; Teppler H;
    Lancet Infect Dis; 2013 Jul; 13(7):587-96. PubMed ID: 23664333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.
    Ananworanich J; Chomont N; Fletcher JL; Pinyakorn S; Schuetz A; Sereti I; Rerknimitr R; Dewar R; Kroon E; Vandergeeten C; Trichavaroj R; Chomchey N; Chalermchai T; Michael NL; Kim JH; Phanuphak P; Phanuphak N
    J Virus Erad; 2015; 1(2):116-122. PubMed ID: 26835516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.